These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 2536817)

  • 21. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
    Dillner J; Kallin B; Ehlin-Henriksson B; Timar L; Klein G
    Int J Cancer; 1985 Mar; 35(3):359-66. PubMed ID: 2982749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael.
    Masucci MG; Contreras-Salazar B; Ragnar E; Falk K; Minarovits J; Ernberg I; Klein G
    J Virol; 1989 Jul; 63(7):3135-41. PubMed ID: 2470924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
    J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins.
    Young LS; Finerty S; Brooks L; Scullion F; Rickinson AB; Morgan AJ
    J Virol; 1989 May; 63(5):1967-74. PubMed ID: 2539497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.
    Kerr BM; Lear AL; Rowe M; Croom-Carter D; Young LS; Rookes SM; Gallimore PH; Rickinson AB
    Virology; 1992 Mar; 187(1):189-201. PubMed ID: 1310556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.
    Geertsen R; Espander-Jansson A; Dobec M; Price P; Wunderli W; Rymo L
    J Clin Microbiol; 1994 Jan; 32(1):112-20. PubMed ID: 8126164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.
    Cohen JI; Picchio GR; Mosier DE
    J Virol; 1992 Dec; 66(12):7555-9. PubMed ID: 1331538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids.
    Contreras-Brodin BA; Anvret M; Imreh S; Altiok E; Klein G; Masucci MG
    J Gen Virol; 1991 Dec; 72 ( Pt 12)():3025-33. PubMed ID: 1662694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition in infectious mononucleosis. II. Kinetics of sensitization against five EBV-encoded nuclear proteins and the latent membrane protein.
    Szigeti R; Kallin B; Dillner J; Henle G; Henle W; Lerner RA; Rymo L; Timar L; Klein G
    Clin Immunol Immunopathol; 1989 Jun; 51(3):396-405. PubMed ID: 2470542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection.
    Tomkinson B; Kieff E
    J Virol; 1992 Feb; 66(2):780-9. PubMed ID: 1309912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.
    Zhao B; Sample CE
    J Virol; 2000 Jun; 74(11):5151-60. PubMed ID: 10799590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.
    Sculley TB; Apolloni A; Stumm R; Moss DJ; Mueller-Lantczh N; Misko IS; Cooper DA
    Virology; 1989 Aug; 171(2):401-8. PubMed ID: 2548326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    Gregory CD; Rowe M; Rickinson AB
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of EBNA-3 family in fresh B lymphocytes infected with Epstein-Barr virus.
    Sawada K; Yamamoto M; Tabata T; Smith M; Tanaka A; Nonoyama M
    Virology; 1989 Jan; 168(1):22-30. PubMed ID: 2535905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of an Epstein-Barr virus nuclear antigen 2 variant (EBNA 2B) by specific sera.
    Sauter M; Mueller-Lantzsch N
    Virus Res; 1987 Aug; 8(2):141-52. PubMed ID: 2823499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1.
    Tursiella ML; Bowman ER; Wanzeck KC; Throm RE; Liao J; Zhu J; Sample CE
    PLoS Pathog; 2014 Oct; 10(10):e1004415. PubMed ID: 25275486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus-specific T-cell recognition of B-cell transformants expressing different EBNA 2 antigens.
    Wallace LE; Young LS; Rowe M; Rowe D; Rickinson AB
    Int J Cancer; 1987 Mar; 39(3):373-9. PubMed ID: 3493225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.